We invest in start-up companies with differentiated core strengths, high-growth prospects, asset-light business models, and huge market potential.
We invest in companies with strong growth potential and competitive advantage to grow via IPO or M&A strategies.
We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors.
We seek to seize premium returns in Greater China’s mid-market buyout segment, leveraging on the broader CDF platform and its unique Taiwan heritage in control situations where generational transitions and market transformations lead to attractive buyout opportunities.
We pursue opportunistic investments that achieve attractive risk-adjusted returns, primarily in North America and Asia Pacific. We also invest across the capital structure in control and non-control situations, and are industry-agnostic.
We aim to capture recurring, high yielding cash returns through investing in bespoke and defensively structured, secured debt packages and securitizations of performing and growing middle market borrowers.